Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

November 10, 2017: By Jon Swedien

alimera-sciencesAlimera Sciences posted Q3-2017 net revenues of $9.8 million, an 18 percent increase compared with Q3-2016, the company reported Nov. 1.

The Alpharetta, Georgia-based company markets Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg for the treatment of diabetic macular edema (DME).

Iluvien is the first DME treatment to deliver 36 months of continuous, low-dose corticosteroid with a single injection, Alimera said. It received US approval in September 2014 and is also available in 17 other countries.

Alimera CEO Dan Myers told investors in a conference call Nov. 2 that the company’s sales force was using study data to urge doctors to use Iluvien more frequently.

Typically, doctors have used Iluvien with patients who have not responded well to anti-VEGFs, Myers said. The study data, however, showed that Iluvien could lessen treatment burden for patients whose DME is well controlled by anti-VEGFs, Myers said.

The data he referred to showed that treatment with Iluvien lessened some patients’ need for anti-VEGF injections from once every 2.9 months to once every 22 months, Alimera said.

The study was conducted at four practices, involved more than 20 physicians, and included 130 patients (160 eyes), Myers said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023